VYNE Therapeutics reports Q1 2023 net loss of $5.6M; VYN201 Phase 1b data expected Q3 2023

VYNE Therapeutics Inc.

2023-Q1 EPS reported -$1.74 revenue$99,000

Q1 2023 GAAP net loss $5.6M vs net income $4.7M in Q1 2022; loss from continuing ops improved to $5.6M from $8.7M.
Topline 16-week data for all three cohorts of VYN201 Phase 1b trial in vitiligo expected in Q3 2023.
Lead development candidate selected for VYN202 oral BD2-selective BET inhibitor; IND filing targeted by year-end 2023.
Positive safety and PK data from VYN201 Phase 1a; no serious adverse events or dose adjustments.
Preclinical data for inhaled VYN201 in IPF model showed anti-inflammatory and anti-fibrotic effects.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYNE Therapeutics Inc. reported the three months ended March 31, 2023 results: net income $ (5,622).

Period: the three months ended March 31, 2023
Net income: $ (5,622)
Result: reported results

Exact text from the filing

1 Financial Performance (in thousands) Three Months Ended March 31 2023 2022 Loss from continuing operations (GAAP) $ (5,612) $ (8,694) Adjusted loss from continuing operations (non-GAAP)* $ (4,756) $ (7,449) Net (loss) income (GAAP) $ (5,622) $ 4,670 Adjusted net (loss) income (non-GAAP)* $ (4,766) $ 5,563 *See "

View on SEC.gov

Browse all earnings releases →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-017579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.